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Just as general physicians have become accustomed to the concept of heart failure with preserved ejection fraction (HFpEF), the latest 
        2016 guidelines for the diagnosis and treatment of 
heart failure from the European Society of Cardiology 
(ESC) have introduced a new group of patients: 
those with heart failure with mildly reduced ejection 
fraction (HFmrEF).1 The ESC has explained that this 
new category was needed as a means to fill the gap that 
existed in the knowledge and understanding of heart 
failure as well as stimulating research on this group of 
patients who have not traditionally been included in 
studies on heart failure with reduced ejection fraction 
(HFrEF) or HFpEF.1 
In the 2016 ESC guidelines, the diagnostic criteria 
for HFmrEF includes signs and symptoms of heart 
failure, an ejection fraction (EF) of 40–49%, elevated 
levels of natriuretic peptides and either relevant struc-
tural heart disease (i.e. left ventricular hypertrophy 
and/or left atrial enlargement) or diastolic dysfunction 
observed during echocardiography.1 Interestingly, the 
last two criteria are also used to diagnose HFpEF; 
this new category could therefore be considered to 
constitute either pre-HFrEF or progressive HFpEF, 
assuming that HFpEF is a forerunner of HFrEF.2,3 This 
is supported by the fact that the ventricles of patients 
with HFpEF are not entirely normal and have certain 
contractile abnormalities.4,5
Previous Changes in 
Classifications
In order to ascertain whether the new classification 
of HFmrEF is beneficial, it is useful to reflect on the 
introduction of the term ‘HFpEF’. Prior to the formal 
identification of this group of patients as a distinct 
entity, clinicians were aware that some patients, 
mainly elderly hypertensive females, presented with 
clinical signs of heart failure but displayed normal left 
ventricular function on echocardiography.6 Various 
aetiologies were suggested and these patients were 
initially labelled as having diastolic heart failure, as it 
was believed that these hypertensive patients had stiff 
ventricles that did not relax.6 In the absence of any 
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abstract: The latest European Society of Cardiology (ESC) guidelines for the diagnosis and management of heart 
failure include a new patient group for those with heart failure with mildly reduced ejection fraction (HFmrEF). 
By defining this group of patients as a separate entity, the ESC hope to encourage more research focusing on 
patients with HFmrEF. Previously, patients with this condition were caught between two classifications—heart 
failure with reduced ejection fraction and heart failure with preserved ejection fraction. Hopefully, the inclusion 
of new terminology will not increase confusion, but rather aid our understanding of heart failure, a complex 
clinical syndrome.
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امللخ�ص: �ضملت املبادئ الت�جيهية االأخرية للرابطة االأوروبية لطب القلب لت�ضخي�ص وعالج ف�ضل القلب جمم�عة جديدة من ف�ضل القلب 
مع انخفا�ص قليل يف الك�رس القذيف. ح�ضب تعريف هذة املجم�عة من املر�ضى ككيان منف�ضل, تاأمل الرابطة االأوروبية لطب القلب ت�ضجيع 
املزيد من االأبحاث التي تركز على مر�ضى ف�ضل القلب مع انخفا�ص قليل يف الك�رس القذيف. �ضابقا, املر�ضى امل�ضاب�ن بهذا املر�ص كان�ا 
اإدراج  اأن  ناأمل من  القذيف.  الك�رس  القلب مع حفظ  القذيف و ف�ضل  الك�رس  انخفا�ص  القلب مع  الت�ضنيف-ف�ضل  يدرج�ن حتت ن�عني من 
امل�ضطلح اجلديد لن يزيد من االإرتباك بل بالعك�ص �ضي�ضاعد على فهم ف�ضل القلب والذي يعترب متالزمة �رسيرية معقدة.
الكلمات املفتاحية: ف�ضل القلب؛ الك�رس القذيف البطيني؛ املبادئ الت�جيهية كم��ض�ع؛ ت�ضمية.
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clinical evidence, clinicians often treated this group 
of patients in the same way as those with HFrEF, with 
varying results.7 It was Gandhi et al. who first reported 
38 patients presenting with hypertensive acute pulm- 
onary oedema and preserved left ventricular func- 
tion, both during the acute phase and after success-
ful treatment of their acute presentation, thus demo-
nstrating that these patients constituted a distinct 
entity.8 This patient group was subsequently given 
many labels, such as ‘diastolic heart failure’ and ‘heart 
failure with normal EF’.9 Eventually, the American 
Heart Association and the ESC formally accepted the 
term ‘HFpEF’.10,11
The formal recognition of HFpEF as a distinct 
entity has led to more focused research on this group 
of patients. It is now known that these patients are 
a heterogeneous group not limited to elderly hyper-
tensive females and whose ventricles have normal 
systolic function with varying degrees of stiffness 
and diastolic abnormalities.12 In addition, evidence 
now shows that many of the treatment modalities 
for treating HFrEF are ineffective for patients with 
HFpEF.12 These findings have changed the manage- 
ment of and approach to dealing with patients with 
HFpEF, although there are admittedly still many 
unanswered questions.13 In a similar manner, despite 
the possible initial reluctance to accept another 
category of heart failure patients, the decision by 
the ESC to define HFmrEF may help to increase 
understanding of this disease and improve its treat-
ment, particularly for patients who fall in between the 
two previous categories.
Current Approaches to 
Diagnosis and Management
Clinicians familiar with the management of heart 
failure patients will know that individuals with 
HFmrEF are often difficult to treat. In a way, they are 
somewhat similar to HFpEF patients whereby the 
symptoms of heart failure appear disproportional to 
the level of reduced EF; moreover, these patients do 
not often respond as well to diuretics, angiotensin-
converting enzyme inhibitors or β-blockers.14 Similar 
to the treatment that HFpEF patients received prior 
to breakthroughs in the understanding of the disease, 
HFmrEF patients are still treated with similar 
management plans to those of HFrEF patients.15 
Although there is often no evidence to back up these 
management plans, clinicians tend to rely on their 
clinical experience. Perhaps time will tell whether 
these patients are more likely to respond to conven-
tional heart failure treatments or whether there is a 
need for more specific treatment modalities. Currently, 
the ESC guidelines have combined the management of 
patients with HFmrEF with that of HFpEF patients.1
A major problem in the management of HFpEF, 
and now HFmrEF as well, is establishing the diag-
nosis.16 There is still some reluctance to label a patient 
with preserved left ventricular function as having 
heart failure; as such, HFpEF and HFmrEF patients 
are often underdiagnosed.16 These patients sometimes 
undergo multiple tests to rule out respiratory and 
ischaemic causes of breathlessness before ultimately 
being diagnosed with heart failure. Moreover, HFpEF 
and HFmrEF patient groups are heterogeneous and 
often have multiple comorbidities that can confuse 
the diagnosis.12 There is a danger of both the over- 
and underdiagnosis of heart failure. Epidemiological 
studies have shown that the incidence of HFpEF 
appears to be on the rise.17,18 This could potentially 
be explained by the developing awareness of HFpEF 
on the part of clinicians and their increased willing-
ness to make this diagnosis now that it has been 
officially recognised.
Opportunities for Further 
Research
With the previously undefined group of HFmrEF 
patients now having been legitimised with an official 
name, albeit one difficult to articulate properly, it 
can be hoped that this will spur research focusing 
specifically on this patient group.19 Currently, it is 
unknown whether these patients have a milder version 
of HFrEF, if HFmrEF indicates those with HFpEF 
whose EF is now deteriorating or indeed if it is simply 
a part of the heart failure continuum.19 Along those 
lines, it is not clear whether aggressive treatment of 
HFpEF would prevent patients from progressing 
to HFmrEF or whether aggressive management of 
HFmrEF would prevent patients from deteriorating 
to HFrEF. More research is therefore justified. This 
change in nomenclature gives rise to many questions 
that clinicians have perhaps always asked themselves, 
but never had the chance to openly query; these can 
hopefully now be answered, perhaps via large-scale 
clinical trials.
Alternative Classifications of 
Heart Failure
It must be noted that the use of EF as a method of 
classifying heart failure is not universally agreed upon. 
De Keulenaer et al. argue that HFpEF and HFrEF are 
overlapping phenotypes within the spectrum of heart 
failure and that the use of EF to classify heart failure is 
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not accurate.3 They suggest that this classification came 
about primarily because early heart failure drug trials 
included patients with low EF, who were considered 
a high-risk group, in order to produce statistically 
significant results.3 Subsequently, an emphasis on 
evidence-based medicine has automatically led to the 
use of cut-off values derived from the results of these 
trials. Another suggestion is that the disease be classified 
based on aetiology or physiological abnormalities, as 
well as the clinical presentation of acute or chronic 
heart failure symptoms, as this affects management 
choices.9 Furthermore, by using pathophysiology to 
classify heart failure, other researchers have proposed 
the use of biomarkers either alone or in combination 
with echocardiography in order to guide therapy and 
management choices, instead of relying entirely on 
EF measurements.20–22
Conclusion
Despite the announcement by the ESC of yet another 
category of heart failure patients with a tongue-
twisting acronym, it is unlikely that the clinical 
management of this new HFmrEF patient group will 
change immediately. However, this new classification 
does define another subset of heart failure patients 
on whom additional and more focused research can 
now be conducted. Ideally, this will ensure increased 
understanding of this patient group in order to improve 
and effectively tailor management approaches.
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